Janssen’s Tremfya (guselkumab) Receives EC’s Approval as a First in Class Treatment for Active Psoriatic Arthritis

November 26, 2020 Auto Bot receives, regulatory, Treatment, Tremfya 0

Shots:

  • The approval is based on P-lll DISCOVER-1 & -2 study assessing Tremfya (100mg q4w and q8w) vs PBO in 381 & 739 patients with active PsA who had an inadequate response to SOC &
  • Who were biologic-naïve only and had an inadequate response to SOC respectively
  • Combined results: achieved 1EPs of ACR20 @24wks.; improvements in quality of life scores; improvement in PASI 75, PASI 90, and PASI 100 rates. In DISCOVER-2 study, @24wks. less radiographic progression in both groups Tremfya is the first selective IL-23 p19 subunit inhibitor licensed for both the treatment of PsA and PsO

Click here ­to­ read full press release/ article | Ref: Janssen | Image: The Pharma Letter

The post Janssen’s Tremfya (guselkumab) Receives EC’s Approval as a First in Class Treatment for Active Psoriatic Arthritis first appeared on PharmaShots.